Skip to main content

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma. 

Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharma – one of the first companies that BaseLaunch has financed – for an amount of up to CHF 450 million Swiss francs. T3 Pharma has developed a proprietary therapy platform that uses live bacteria to deliver immune-modulating proteins to cancer cells and tumor micro-environments. 

Despite the significant transformation of the cancer treatment landscape by immunotherapies, long-term remissions only occur in 15-20% of cancer patients. Boehringer Ingelheim aims to considerably increase this rate by utilizing complementary immuno-oncology platforms such as T-Cell Engagers (TcEs), oncolytic viruses, and cancer vaccines, which have the potential to turn cold tumors into hot ones, extending the benefits of immunotherapy to more patients in need. 

T3 Pharma’s pioneering technology will bolster Boehringer Ingelheim’s array of novel immune-modulatory cancer treatments, reinforcing the company’s oncology strategy to transform the lives of people affected by cancer. 

Read more in T3 pharma`s official press release. 

Share this article

View all news

Sign up to receive our newsletter in your inbox.